- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04422028
Bioavailability of Desogestrel 0.075 mg Tablets With Regards to Reference Product
Bioavailability of a Formulation of Desogestrel 0.075 mg Coated Tablets With Regards to the Marketed Reference Product
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of the study is to investigate the relative bioavailability of Desogestrel of 2 tablet formulations with Desogestrel 0.075 mg to demonstrate bioequivalence of both formulations in terms of rate and extent of absorption:
- Test Product: Product manufactured by Laboratorios Andrómaco S.A.
- Reference Product: Cerazette [Trademark], product of Merck Sharp and Dohme Ltda., Brasil.
The 90% confidence intervals for the intra-subject coefficient of variation (Test versus Reference Product) for the main pharmacokinetic parameters area under the plasma concentration-time curve from time zero to time t (AUC0-t) and from time zero to 72 hours (AUC0-72), and maximum plasma concentration (Cmax) for total metabolite etonogestrel was determined.
Participants were confined in the study site for approximately 36 hours during each study period (for 12 hours pre-dosing and for 24 hours post dosing) during which pharmacokinetic (PK) blood samples were obtained. 16 blood samples were taken up to 24 hours after the administration in each period. Participants returned to the site to provide additional blood samples at 48 h, and 72 h postdose.
The washout period between the two study periods was 14 days. The samples from each participant were analyzed with 2 methods of highperformance liquid chromatography-tandem mass spectrometry bioanalytical assays to quantify total Dienogest and Ethinyl estradiol in plasma.
The safety objective was to evaluate the tolerability of both formulations in women by collecting adverse events.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Santiago, Chile
- Innolab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-pregnant and non-breastfeeding women
- Women of childbearing age with an acceptable form of contraception during the study
- 18 to 55 years old inclusive; BMI greater than or equal to 18.51 and less than or equal to 29.99
- Non-smoking or smoke only 3 cigarettes every 7 days
- With results of laboratory tests, electrocardiogram and chest radiography in normal and / or negative or abnormal ranges but without clinical relevance and declared suitable for study by the doctor after the physical examination
- Capable to understand the Informed Consent Form
Exclusion Criteria:
- Study site staff or sponsor staff or family members
- With history of drug and/or alcohol abuse
- Smokers more tan 3 cigarettes every 7 days
- Vitamin supplements intake 7 days prior to the administration of the medications under study
- Any recent change in eating habits or physical exercise
- Using of a pharmacological therapy (except over the counter medication use 7 days prior to the study)
- Hypersensitivity to the study drug or to other chemically related compounds, history of serious adverse reactions or hypersensitivity to any medication
- Use, during the 28 days prior to the start of the study, of medications known to alter liver enzyme activity
- Consumption of beverages or food containing grapefruit or pink grapefruit, within 7 days prior to each administration of the study medication and consumption of alcohol, caffeine or beverages or foods containing xanthines 24 hours before each administration of the study medication until the last sample of each period
- History of any significant cardiovascular disease
- Acute disease that generates significant physiological changes from the time of selection until the end of the study
- HIV, Hepatitis B and/or C positive
- Presence or history of thrombophlebitis, thrombosis or thromboembolic disorders, deep vein thrombosis, pulmonary embolism or known coagulopathy.
- Donation or loss of a significant volume (more than 100 mL) of blood or plasma or platelets during the 3 months prior to the start of the study
- Subjects who have participated in any type of clinical study during the 3 months prior to the start of the study
- History of any gastrointestinal surgery that could affect drug absorption
- Presence of fainting history or fear to blood collection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Desogestrel Test Product
Participants received two tablets of the test formulation containing Desogestrel 0.075 mg.
The tablets were taken with water and in a fasting condition.
|
Test Drug
Other Names:
Reference Product
Other Names:
|
ACTIVE_COMPARATOR: Desogestrel Reference Product
Participants received two tablets of the marketed reference formulation containing Desogestrel 0.075 mg.
The tablets were taken with water and in a fasting condition.
|
Test Drug
Other Names:
Reference Product
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total etonogestrel: area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72).
Time Frame: From tablet intake and up to 72 hours after tablet intake.
|
19 samples up to 72 hours will be taken after the administration in each period.
|
From tablet intake and up to 72 hours after tablet intake.
|
Total etonogestrel: area under the plasma concentration-time curve from 0 to time t (AUC0-t)
Time Frame: From tablet intake and up to 72 hours after tablet intake.
|
19 samples up to 72 hours will be taken after the administration in each period.
|
From tablet intake and up to 72 hours after tablet intake.
|
Total etonogestrel: Maximum plasma concentration (Cmax)
Time Frame: From tablet intake and up to 72 hours after tablet intake
|
19 samples up to 72 hours will be taken after the administration in each period.
|
From tablet intake and up to 72 hours after tablet intake
|
Total etonogestrel: Time to achieve maximum plasma concentration (tmax)
Time Frame: From tablet intake and up to 72 hours after tablet intake
|
19 samples up to 72 hours will be taken after the administration in each period.
|
From tablet intake and up to 72 hours after tablet intake
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Study Director Study Director, Laboratorios Andromaco
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Progestins
- Desogestrel
Other Study ID Numbers
- HP8824-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioequivalence
-
Pharmtechnology LLCRecruitingBioequivalenceRussian Federation
-
Emzor Pharmaceutical Industries LimitedNot yet recruiting
-
Pharmtechnology LLCClinPharmInvest, LLCNot yet recruitingBioequivalenceRussian Federation
-
Indiana UniversityFood and Drug Administration (FDA)Completed
-
AstraZenecaCompletedBioequivalenceUnited States
-
Future University in EgyptCompleted
-
Cross Research S.A.Zambon SpACompleted
-
Laboratorios Andromaco S.A.Completed
-
Emzor Pharmaceutical Industries LimitedUnknown
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
Clinical Trials on Desogestrel 0.075 MG
-
Casa di Cura Privata Villa MafaldaRecruiting
-
Revogenex, Inc.Suspended
-
Integro TheranosticsRecruitingBreast Cancer | DCIS | Invasive Duct Carcinoma of BreastUnited States
-
University Hospital, GenevaTerminatedContraception | Progestogen Adverse Reaction
-
Centre Hospitalier Intercommunal CreteilMerck Sharp & Dohme LLCCompleted
-
Associazione Qol-oneRecruitingMyelodysplastic Syndromes | Anemia | Transfusion-dependent Anemia | Del(5Q)Italy
-
VL-Medi OyMerck Sharp & Dohme LLCUnknown
-
Yale UniversityWithdrawn
-
Bio-innova Co., LtdNot yet recruiting
-
Chulalongkorn UniversityCompletedPremenstrual SyndromeThailand